| INTRODUCTION
Equine influenza virus (EIV) of the H3N8 subtype is associated with an acute respiratory disease which has immense economic relevance due to its highly contagious nature and potential to disrupt equestrian events. 1, 2 Each equine influenza (EI) virion contains 8 segments of negative sense viral RNA named; PB2, PB1, PA, HA, NP, NA, M and NS.
These segments encode at least 10 proteins which include the surface glycoproteins; haemagglutinin (HA) and neuraminidase (NA), the matrix ion channel (M2), the matrix protein (M1), three polymerases (PA, PB1 and PB2), the structural nucleoprotein (NP), the non-structural protein (NS1), the nuclear export protein (NEP), an accessory proapoptotic protein (PB1-F2) 3 and a recently discovered PA-X protein. 4 The HA glycoprotein is particularly important in the evolution of EIV as it stimulates a strong humoral antibody response following infection. 5, 6 Mutations in the HA lead to antigenic drift and emergence of antigenically distinct EIV lineages. Subsequent to EI epizootics in 1989, phylogenetic analysis of the HA gene revealed divergence of the circulating H3N8 viruses into the Eurasian and American lineages. 7 In the 1990s, the American lineage diverged into the South America, Kentucky and Florida sublineages. 8 More recently, the Florida sublineage has predominated and evolved into 2 additional distinct clades, 16 In endemic populations, EIV persists due to the existence of susceptible partially vaccinated or unvaccinated horses and compromised vaccine effectiveness, which occurs as a result of antigenic mismatch between vaccine and field strain viruses. 17, 18 Experimentally infected animals vaccinated with a heterologous vaccine strain shed virus for longer than those that received a homologous vaccine. 19 In countries which are free from EI, the virus has frequently been introduced by the importation of infected vaccinated horses. 20, 21 Thus, it is extremely important that the equine industry has access to epidemiologically relevant vaccines. To achieve this aim, phylogenetic and 
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| MATERIALS AND METHODS
| Clinical detection
Nasopharyngeal swabs and serum samples were collected from 7 clinically affected horses. The nasopharyngeal swabs were tested by panreactive influenza type A real-time RT-PCR (qRT-PCR) described by 
| Virus isolation
Isolation of viruses from three EI qRT-PCR-positive nasopharyngeal swabs (A/equine/Ankara/1/2013, A/equine/Ankara/2/2013 and A/ equine/Ankara/3/2013) was carried out in 10-day-old embryonated hens' eggs. 24 A/equine/Ankara/1/2013 had the highest HA titre following initial passage and was therefore selected for repeat passage to reach the required concentration for sequencing (HA of 1:128).
| Antigenic characterisation
A/equine/Ankara/1/2013 was antigenically characterised by the haemagglutination inhibition (HI) test using clade-specific ferret antisera pre-treated with heat and periodate. Geometric mean titres were calculated for three HI tests for each combination.
| Whole-genome sequencing
A/equine/Ankara/1/2013 was passaged twice in embryonated hens' eggs and diluted to 10 6 EID 50 /mL. RNA was extracted using QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany). For whole-genome sequencing (WGS), one-step PCR was undertaken using SuperScript ™ III One-Step RT-PCR System with Platinum ® Taq High Fidelity (Invitrogen, Carlsbad, California, USA) using overlapping M-13 labelled primers for each of the 8 EIV segments. 25 An additional NA primer (5′-GCCTCACAAAGTGGTTC-3′) was designed to obtain the start of the NA gene. Table S1 for Table S2 for accession codes).
| RESULTS
| Disease outbreak
Between 11 affected horses were quarantined, and temporary movement restrictions were imposed. 
| Laboratory confirmation
| Antigenic characterisation
Antigenic characterisation identified A/equine/Ankara/1/2013 as a FC2 strain of EIV (Table 1) . A panel of specific antisera raised against FC2 viruses demonstrated similarly high HI titres for A/equine/Ankara/1/2013
as they did against their homologous virus. Additionally, up to an eightfold higher titre was observed with A/equine/Ankara/1/2013 for FC2 than FC1 antisera which confirmed the FC2 classification.
| Phylogenetic classification (HA1 and NA)
A maximum-likelihood phylogenetic tree confirmed that A/equine Ankara/1/2013 is an FC2 strain as it clustered with other isolates in that clade that have the I179V substitution, that is the "179 group" 
| Whole-genome sequencing
Whole-genome sequencing was achieved using overlapping Table 2 ).
Within the RNA-dependent polymerase complex (PB2, PB1 and PA), a total of 3 (S107N, R389K and R586K), 3 (E75K, T221A and H456Y) and 7 (K22R, D27N, A100T, K158R, M210T, D394N and T A B L E 1 Antigenic characterisation of A/equine/Ankara/1/2013 using ferret antisera The results are summarised in Table 2 Table S1 substitutions that emerged around 2007 (E291D) and 2010 (P103L and V112I). Table S1 but the other seven substitutions appear to be unique to A/equine/ Ankara/1/2013. Of the five substitutions in the NS1, only one is highly 
| DISCUSSION
The EI genome is subject to a slower rate of evolution than other mammalian influenza viruses; however, mutability as measured by the ratio of non-synonymous to synonymous nucleotide mutations (dN/ dS) was not significantly different for equine, 31 avian 32 or swine influenza viruses. 33 Therefore, the genome of EIV has the potential to experience significant antigenic drift in a similar but decelerated time frame to avian and swine influenza. 31 tential future EIV infection. 35 Strategic vaccination preceding travel and participation in racing events optimises antibody levels during periods of heightened risk of exposure. 37 However, periods of immunological susceptibility and the mixing of naïve horses with vaccinated horses can lead to outbreaks of influenza. 38, 39 It is preferable to apply mandatory vaccination to all horses that enter a facility irrespective of their activities as seronegative horses are frequently the index case in an outbreak. 39 The amount of virus they shed coupled with frequent coughing represents a threat to their vaccinated companions, who may then become infected and succumb to influenza. However, at Ankara racetrack the affected horses were effectively quarantined, thus reducing the spread of the virus. Furthermore although the vaccine routinely used at Ankara had not been updated in line with the OIE recommendations, the regular vaccination of the racing horses at six monthly intervals appeared to have induced a protective immunity as only minimal clinical signs, that is transient pyrexia of 38.6-40°C and slight serous nasal discharge, were observed in these horses. This was in contrast to the younger unvaccinated horses that were described as having a hacking cough. that the index case of FC2 was transported to Sweden from Spain through the Netherlands. 13 Other studies, based primarily on HA1
analysis, have also shown the ease with which EIV can spread as a result of transport of horses across Europe, 5 specifically within Ireland, 24 the UK 30 and France.
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AA, amino acid. A/equine/Richmond/1/2007 PA-X protein C-terminal is truncated, not shown. Accession numbers are summarised in Table S2 .
Vaccinated horses arriving at the racecourse have the potential to shed virus without displaying clinical signs of infection. In Hong Kong in 1992, an outbreak of EI was attributed to the importation of vaccinated horses from the UK and Ireland. 42 The incursion re- and FC2 NS1 amino acid sequences cluster separately. 45 The A/ equine/Ankara/1/2013 NS1 amino acid sequence is closely related to the NS1 sequences of viruses in the 179 group and does not have some of the substitutions that are highly conserved in viruses of the 144 group (Fig. S3.11) . Mutations within the functional domain of NS1 protein have been associated with increased virulence in mice, humans and chickens. 46 The significance of unique substitutions observed in the amino acid sequence of A/equine/Ankara/1/2013 is currently undetermined; however, they are located within NS1′s which possess a non-inflammatory motif (amino acid L62, H75 and Q79) (Fig. S3.3 ).
In conclusion, the outbreak of respiratory disease at the race- 
